Orforglipron vs Tesofensine

Orforglipron wins for safety profile (cardiometabolic risk reduction), ease of dosing (true oral), minimal titration friction, and fit for longer or maintenance protocols. Tesofensine wins for raw appetite suppression (especially in GLP-1 resistant scenarios), speed of effect, and as a cut-phase stall-breaker where food noise breaks through peptide satiety.

Pick Orforglipron if:

• Maximizing appetite suppression with GI-manageable, cardio-friendly safety is a priority
• Oral administration and minimal injection hassle is non-negotiable
• A protocol requires flexible food timing—not strict fasted protocols
• Maintenance or post-peptide GLP-1 anchoring is desired
• Cardiometabolic risk factors (BP, lipids, glucose) need to move in the right direction

Pick Tesofensine if:

• Appetite returns mid-GLP-1 protocol and nothing else is holding the floor
• Tolerance has developed to semaglutide/tirzepatide and a mechanistic shift is needed
• The protocol needs maximum satiety drive, regardless of stimulant-related cardiovascular side effects
• A shorter, high-impact cut-phase or contest prep appetite anchor is required
• Stimulant-related euphoria or energy is considered a net benefit